Education
About Us
Working with TipRanks
Follow Us
Guardian Pharmacy Services, Inc. Class A (GRDN)
NYSE:GRDN
Top Page
Guardian Pharmacy Services, Inc. Class A
(NYSE:GRDN)
Select Model
Select Model
Rating:54Neutral
Price Target:
$29.00
▼(-6.90% Downside)
Guardian Pharmacy Services shows strong growth potential with increased guidance and strategic acquisitions. However, financial risks due to high leverage and operational inefficiencies, combined with a high P/E ratio, temper the overall attractiveness of the stock.
Positive Factors
Revenue Growth
Guardian's strong revenue growth, fueled by organic expansion and acquisitions, indicates robust market demand and effective business strategies.
Strategic Acquisitions
Strategic acquisitions in new regions enhance Guardian's market position and growth potential, supporting long-term revenue and market share expansion.
Cash Generation
Strong cash generation provides financial flexibility, enabling Guardian to invest in growth opportunities and manage potential financial challenges.
Negative Factors
High Leverage
Significant leverage without equity raises concerns about financial stability and limits the company's ability to absorb economic shocks.
Operational Inefficiencies
Inefficiencies impacting profitability suggest potential challenges in cost management and operational execution, affecting long-term margins.
Regulatory Challenges
Regulatory uncertainties can disrupt operations and increase compliance costs, posing risks to Guardian's strategic execution and profitability.
Guardian Pharmacy Services, Inc. Class A (GRDN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.94B
Dividend YieldN/A
Average Volume (3M)348.83K
Price to Earnings (P/E)48.9
Beta (1Y)0.63
Revenue Growth18.68%
EPS GrowthN/A
CountryUS
Employees3,400
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)0.25
Shares Outstanding36,253,742
10 Day Avg. Volume450,542
30 Day Avg. Volume348,833
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)8.81
Price to Sales (P/S)1.02
P/FCF Ratio30.20
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue1.20
Enterprise Value/Gross Profit6.10
Enterprise Value/Ebitda20.36
Forecast
1Y Price Target
$34.50Price Target Upside10.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Guardian Pharmacy Services, Inc. Class A Business Overview & Revenue Model
Company DescriptionGuardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.
How the Company Makes MoneyGuardian Pharmacy Services generates revenue through multiple key streams. The primary source of income comes from the dispensing of prescription medications and over-the-counter products to long-term care facilities, where they have established contracts to serve as the preferred pharmacy provider. Additionally, the company earns fees from medication management services, which include consulting and compliance support for healthcare providers. Significant partnerships with healthcare organizations and payers enhance revenue stability, while the growing demand for specialized pharmacy services in the aging population drives further growth in earnings. By leveraging technology and optimizing pharmacy operations, Guardian Pharmacy also aims to reduce costs and increase efficiency, contributing positively to its revenue model.
Guardian Pharmacy Services, Inc. Class A Earnings Call Summary
Earnings Call Date:Nov 10, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Apr 01, 2026
Earnings Call Sentiment Neutral
Guardian Pharmacy reported strong financial growth and increased guidance for the year, driven by successful acquisitions and organic growth. However, regulatory challenges and the dilutive impact of recent acquisitions present ongoing challenges. The positive financial performance and strategic expansions are tempered by these operational and external pressures.Q3-2025 Updates
Positive Updates
Revenue Growth and Financial Performance
Guardian Pharmacy reported a revenue increase of 20% to $377 million, driven by both organic growth and acquisitions. Adjusted EBITDA grew 19% to $27 million, with margins holding steady at 7.2%.
Resident Growth
The company experienced a 13% growth in resident count, reaching nearly 204,000 residents, primarily due to new facility partnerships and expansions.
Acquisitions in Pacific Northwest
Guardian Pharmacy successfully acquired pharmacies in Oregon and Washington, expanding its footprint in the Pacific Northwest and enhancing its growth potential in the region.
Increased Guidance for 2025
The company raised its full-year revenue guidance to $1.43 billion to $1.45 billion and adjusted EBITDA guidance to $104 million to $106 million, reflecting solid growth expectations.
Strong Financial Position
Guardian Pharmacy ended the quarter with $36 million in cash, highlighting strong cash generation and no debt outstanding under its credit facility.
Negative Updates
Inflation Reduction Act Impact
The Inflation Reduction Act presents ongoing challenges for the industry, though Guardian is working on strategic actions to offset anticipated EBITDA headwinds.
Dilutive Impact of Recent Acquisitions
Recent acquisitions have been dilutive to overall margins, with the most recent ones still affecting EBITDA margins negatively.
Policy and Regulatory Challenges
Guardian Pharmacy is navigating complex policy and regulatory environments, including negotiations with PBMs under NDAs, which add uncertainty to future operations.
Company Guidance
In the third quarter earnings call for 2025, Guardian Pharmacy Services reported robust financial performance, exhibiting double-digit growth across key metrics. Revenue surged by 20% to $377 million, driven by a 13% increase in resident count and strategic acquisitions. Adjusted EBITDA rose by 19% to $27 million, maintaining a margin of 7.2%. The adjusted earnings per share (EPS) stood at $0.25. Given this strong performance, Guardian raised its full-year revenue guidance to between $1.43 billion and $1.45 billion, and adjusted EBITDA guidance to between $104 million and $106 million. The company continues to navigate the policy challenges posed by the Inflation Reduction Act while focusing on organic growth, strategic acquisitions, and operational efficiencies to sustain its market leadership in serving assisted living facilities. Guardian's acquisition pipeline remains robust, with recent expansions into Oregon and Washington contributing to its growth momentum.Guardian Pharmacy Services, Inc. Class A Financial Statement Overview
Summary
Guardian Pharmacy Services faces significant profitability and leverage challenges. Despite positive revenue growth, operational inefficiencies have led to recent losses. The absence of equity highlights financial risks, while stable cash flow offers some operational reassurance. Strategic adjustments are necessary to address profitability and balance sheet constraints.Income Statement
Gross profit margin has remained relatively stable while revenue growth has been positive over the years. However, the company faced significant challenges in the latest year, with negative EBIT and net income, highlighting operational inefficiencies and profitability issues.40
Negative
Balance Sheet
The balance sheet shows high leverage with no stockholders' equity for the past years, indicating significant financial risk. The debt-to-equity ratio cannot be calculated due to zero equity, suggesting potential solvency concerns.30
Negative
Cash Flow
The company managed to maintain positive operating and free cash flows, indicating decent cash management. However, the free cash flow growth rate is inconsistent, and the reliance on cash flow to sustain operations due to negative net income is a concern.55
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.39B | 1.23B | 1.05B | 908.91M | 792.07M | 735.96M |
| Gross Profit | 274.32M | 244.37M | 208.31M | 185.87M | 161.26M | 147.00M |
| EBITDA | 82.19M | -43.43M | 58.81M | 68.15M | 46.49M | 49.07M |
| Net Income | 40.24M | -87.29M | 23.90M | 35.42M | 16.31M | 19.94M |
Balance Sheet | ||||||
| Total Assets | 390.04M | 320.81M | 271.17M | 256.11M | 235.85M | 217.87M |
| Cash, Cash Equivalents and Short-Term Investments | 36.49M | 4.66M | 752.00K | 607.00K | 15.01M | 6.45M |
| Total Debt | 34.08M | 37.33M | 69.15M | 62.98M | 55.04M | 58.84M |
| Total Liabilities | 194.54M | 170.83M | 211.31M | 180.18M | 182.53M | 150.80M |
| Stockholders Equity | 183.76M | 142.67M | 28.21M | 42.73M | 23.93M | 38.48M |
Cash Flow | ||||||
| Free Cash Flow | 45.21M | 41.59M | 56.26M | 31.75M | 49.22M | 44.27M |
| Operating Cash Flow | 59.82M | 57.96M | 70.82M | 48.52M | 58.50M | 52.61M |
| Investing Cash Flow | -25.17M | -30.41M | -13.44M | -17.90M | -13.15M | -12.18M |
| Financing Cash Flow | -53.05M | -23.64M | -57.23M | -45.03M | -36.79M | -34.26M |
Guardian Pharmacy Services, Inc. Class A Technical Analysis
Positive
31.15
Price Trends
28.25
Positive
26.65
Positive
24.20
Positive
Market Momentum
0.59
Negative
59.23
Neutral
70.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRDN, the sentiment is Positive. The current price of 31.15 is above the 20-day moving average (MA) of 29.37, above the 50-day MA of 28.25, and above the 200-day MA of 24.20, indicating a bullish trend. The MACD of 0.59 indicates Negative momentum. The RSI at 59.23 is Neutral, neither overbought nor oversold. The STOCH value of 70.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRDN.
Guardian Pharmacy Services, Inc. Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $9.02B | 24.33 | 11.39% | ― | 3.51% | 29.65% | |
70 Neutral | $66.53B | 43.08 | 144.31% | 0.66% | 9.31% | 5.92% | |
66 Neutral | $47.15B | 29.96 | ― | 1.02% | 4.37% | 28.48% | |
62 Neutral | $99.55B | 25.11 | ― | 0.38% | 17.23% | 66.17% | |
54 Neutral | $1.94B | 48.94 | 25.85% | ― | 18.68% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | $240.55M | -0.18 | -184.47% | ― | -37.09% | -2639.44% |
* Healthcare Sector Average
GRDN
Guardian Pharmacy Services, Inc. Class A
31.15
9.31
42.63%
COR
Cencora
340.58
116.04
51.68%
CAH
Cardinal Health
199.10
83.76
72.62%
HSIC
Henry Schein
77.02
8.07
11.70%
MCK
McKesson
810.56
233.78
40.53%
OMI
Owens & Minor
3.15
-9.47
-75.04%
Guardian Pharmacy Services, Inc. Class A Corporate Events
Business Operations and Strategy
Guardian Pharmacy Locks Up Majority of Shares
Neutral
Oct 14, 2025
On October 14, 2025, Guardian Pharmacy Services, Inc. announced that it has entered into lock-up agreements with holders of approximately 93% of its outstanding Class A and Class B common stock. These agreements restrict the sale or transfer of shares held by the company’s founders, executive officers, and employees until June 30, 2026, impacting 17,188,059 Class A shares and 12,759,054 Class A shares issuable upon conversion of Class B shares. This move aims to stabilize the company’s stock following its initial public offering on September 27, 2024, and maintain market confidence.
Business Operations and StrategyFinancial Disclosures
Guardian Pharmacy Highlights Strategic Initiatives in ALF Market
Positive
Sep 18, 2025
Guardian Pharmacy Services, Inc. has released a presentation intended for investors and analysts, highlighting its strategic initiatives and market positioning. The company emphasizes its competitive advantages through a tech-enabled, service-led model, aiming for above-sector growth and profitability. The presentation outlines Guardian’s focus on the ALF market, which is characterized by a high demand for medication management due to the rising age and acuity of residents. The company’s strong financial performance, experienced management team, and significant market share position it as a leader in the highly fragmented ALF pharmacy market.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.